| 000 | 01696 a2200481 4500 | ||
|---|---|---|---|
| 005 | 20250513221629.0 | ||
| 264 | 0 | _c20010126 | |
| 008 | 200101s 0 0 eng d | ||
| 022 | _a1522-8002 | ||
| 024 | 7 |
_a10.1038/sj.neo.7900102 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aRubenstein, J L | |
| 245 | 0 | 0 |
_aAnti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption. _h[electronic resource] |
| 260 |
_bNeoplasia (New York, N.Y.) _c |
||
| 300 |
_a306-14 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S. | ||
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aAntibodies _xtherapeutic use |
| 650 | 0 | 4 |
_aBrain Neoplasms _xblood supply |
| 650 | 0 | 4 |
_aEndothelial Growth Factors _xantagonists & inhibitors |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aGlioblastoma _xblood supply |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aIn Situ Nick-End Labeling |
| 650 | 0 | 4 |
_aLymphokines _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aNeovascularization, Pathologic _xprevention & control |
| 650 | 0 | 4 | _aRats |
| 650 | 0 | 4 | _aRats, Nude |
| 650 | 0 | 4 | _aSurvival Rate |
| 650 | 0 | 4 | _aTime Factors |
| 650 | 0 | 4 | _aTransplantation, Heterologous |
| 650 | 0 | 4 | _aTumor Cells, Cultured |
| 650 | 0 | 4 | _aVascular Endothelial Growth Factor A |
| 650 | 0 | 4 | _aVascular Endothelial Growth Factors |
| 700 | 1 | _aKim, J | |
| 700 | 1 | _aOzawa, T | |
| 700 | 1 | _aZhang, M | |
| 700 | 1 | _aWestphal, M | |
| 700 | 1 | _aDeen, D F | |
| 700 | 1 | _aShuman, M A | |
| 773 | 0 |
_tNeoplasia (New York, N.Y.) _gvol. 2 _gno. 4 _gp. 306-14 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1038/sj.neo.7900102 _zAvailable from publisher's website |
| 999 |
_c10951504 _d10951504 |
||